Skip Nav Destination
Issues
1 May 2023
-
Cover Image
Cover Image
The figure shows a section of a brain tumor biopsy from a patient with primary CNS lymphoma. Immunohistochemical staining reveals diffuse immune infiltration (CD45, yellow) characterized by high phospho-IRAK4 (red) expression, interspersed with tumor-reactive astrocytes (GFAP, green). DAPI nuclear stain (blue) is included to illustrate cellularity of the tissue. For details, see the article by Von Roemeling and colleagues on page 1751 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Jaleh Fallah; Sundeep Agrawal; Haley Gittleman; Mallorie H. Fiero; Sriram Subramaniam; Christy John; Wei Chen; Tiffany K. Ricks; Gang Niu; Anthony Fotenos; Min Wang; Kelly Chiang; William F. Pierce; Daniel L. Suzman; Shenghui Tang; Richard Pazdur; Laleh Amiri-Kordestani; Amna Ibrahim; Paul G. Kluetz
Review
Perspectives
The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice
Alex Broom; Leah Williams Veazey; Katherine Kenny; Imogen Harper; Michelle Peterie; Alexander Page; Nicole Cort; Jennifer Durling; Eric S. Lipp; Aaron C. Tan; Kyle M. Walsh; Brent A. Hanks; Margaret Johnson; Amanda E.D. Van Swearingen; Carey K. Anders; David M. Ashley; Mustafa Khasraw
Clinical Trials: Targeted Therapy
Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
Robert E. Schoen; Lisa A. Boardman; Marcia Cruz-Correa; Ajay Bansal; David Kastenberg; Chin Hur; Lynda Dzubinski; Sharon F. Kaufman; Luz M. Rodriguez; Ellen Richmond; Asad Umar; Eva Szabo; Andres Salazar; John McKolanis; Pamela Beatty; Reetesh K. Pai; Aatur D. Singhi; Camille M. Jacqueline; Riyue Bao; Brenda Diergaarde; Ryan P. McMurray; Carrie Strand; Nathan R. Foster; David M. Zahrieh; Paul J. Limburg; Olivera J. Finn
Clinical Trials: Immunotherapy
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
Peter Anderson; Maurizio Ghisoli; Brian D. Crompton; Kelly S. Klega; Leonard H. Wexler; Emily K. Slotkin; Laura Stanbery; Luisa Manning; Gladice Wallraven; Meghan Manley; Staci Horvath; Ernest Bognar; John Nemunaitis
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Charles N. Landen; Luciana Molinero; Habib Hamidi; Jalid Sehouli; Austin Miller; Kathleen N. Moore; Cagatay Taskiran; Michael Bookman; Kristina Lindemann; Charles Anderson; Regina Berger; Tashanna Myers; Mario Beiner; Thomas Reid; Els Van Nieuwenhuysen; Andrew Green; Aikou Okamoto; Carol Aghajanian; Premal H. Thaker; Stephanie V. Blank; Victor K. Khor; Ching-Wei Chang; Yvonne G. Lin; Sandro Pignata
Precision Medicine and Imaging
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Roberto Carmagnani Pestana; Justin T. Moyers; Jason Roszik; Shiraj Sen; David S. Hong; Aung Naing; Cynthia E. Herzog; Siqing Fu; Sarina A. Piha-Paul; Jordi Rodon; Timothy A. Yap; Daniel D. Karp; Apostolia M. Tsimberidou; Shubham Pant; Maria A. Zarzour; Ravin Ratan; Vinod Ravi; Robert S. Benjamin; Alexander J. Lazar; Wei-Lien Wang; Najat Daw; Jonathan B. Gill; Douglas J. Harrison; Valerae O. Lewis; Christina L. Roland; Shreyaskumar R. Patel; J. Andrew Livingston; Neeta Somaiah; Joseph A. Ludwig; Anthony P. Conley; Nelson Hamerschlak; Richard Gorlick; Funda Meric-Bernstam; Vivek Subbiah
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Andrew A. Davis; Jingqin Luo; Tiantian Zheng; Chao Dai; Xiaoxi Dong; Lu Tan; Rama Suresh; Foluso O. Ademuyiwa; Caron Rigden; Timothy P. Rearden; Katherine Clifton; Katherine Weilbaecher; Ashley Frith; Pavan K. Tandra; Tracy Summa; Brittney Haas; Shana Thomas; Leonel F. Hernandez-Aya; Lindsay L. Peterson; Xiaohong Wang; Shujun J. Luo; Kemin Zhou; Pan Du; Shidong Jia; Bonnie L. King; Jairam Krishnamurthy; Cynthia X. Ma
Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Zhiyuan Bo; Bo Chen; Zhengxiao Zhao; Qikuan He; Yicheng Mao; Yunjun Yang; Fei Yao; Yi Yang; Ziyan Chen; Jinhuan Yang; Haitao Yu; Jun Ma; Lijun Wu; Kaiyu Chen; Luhui Wang; Mingxun Wang; Zhehao Shi; Xinfei Yao; Yulong Dong; Xintong Shi; Yunfeng Shan; Zhengping Yu; Yi Wang; Gang Chen
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Katleen Janssens; Greetje Vanhoutte; Willem Lybaert; Wim Demey; Jochen Decaestecker; Koen Hendrickx; Hassan Rezaei Kalantari; Karen Zwaenepoel; Patrick Pauwels; Erik Fransen; Ken Op de Beeck; Guy Van Camp; Christian Rolfo; Marc Peeters
Translational Cancer Mechanisms and Therapy
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Christina A. Von Roemeling; Bently P. Doonan; Kelena Klippel; Daniel Schultz; Lan Hoang-Minh; Vrunda Trivedi; Chenglong Li; Rylynn A. Russell; Raju S. Kanumuri; Abhisheak Sharma; Han W. Tun; Duane A. Mitchell
Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Stephen V. Carney; Kaushik Banerjee; Anzar Mujeeb; Brandon Zhu; Santiago Haase; Maria L. Varela; Padma Kadiyala; Claire E. Tronrud; Ziwen Zhu; Devarshi Mukherji; Preethi Gorla; Yilun Sun; Rebecca Tagett; Felipe J. Núñez; Maowu Luo; Weibo Luo; Mats Ljungman; Yayuan Liu; Ziyun Xia; Anna Schwendeman; Tingting Qin; Maureen A. Sartor; Joseph F. Costello; Daniel P. Cahill; Pedro R. Lowenstein; Maria G. Castro
Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Axel Stenmark Tullberg; Martin Sjöström; Emma Niméus; Fredrika Killander; S. Laura Chang; Felix Y. Feng; Corey W. Speers; Lori J. Pierce; Anikó Kovács; Dan Lundstedt; Erik Holmberg; Per Karlsson
Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers
Elie Rassy; Ingrid Garberis; Alicia Tran-Dien; Bastien Job; Véronique Chung-Scott; Ibrahim Bouakka; Josiane Bassil; Rachel Ferkh; Magali Lacroix-Triki; Fabrizio Zanconati; Fabiola Giudici; Daniele Generali; Etienne Rouleau; Ludovic Lacroix; Fabrice Andre; Barbara Pistilli
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds